Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.

We evaluated delta-9 tetrahydrocannabinol (Delta9-THC), delta-8 tetrahydrocannabinol (Delta8-THC), CP55,940 (CP55), 1-deoxy-11-hydroxy-Delta8-THC-dimethylheptyl (deoxy-HU210, a CB2-selective cannabinoid that also binds the CB1 receptor) and the endogenous cannabinoid anandamide (ANA) via i.c.v. and/or intrathecal (i.t.) routes of administration, alone and in combination with SR141716A (SR), a CB1 antagonist, using the tail-flick test. Our studies were performed in order better to characterize potential diversity in interactions of the cannabinoids with the cannabinoid (CB1) receptor. When SR was administered i.c.v. or i.p. before Delta9-THC, Delta8-THC or CP55 (i.c.v. or i.t.), SR was a potent antagonist and the blockade was complete (AD50 </= 8.1 microgram/mouse i.c.v. or AD50 </= 1.4 mg/kg i.p.). The AD50 values (dose of antagonist that produced a 50% antagonism of agonist effects) for blockade of Delta9-THC, Delta8-THC, CP55,940 (i.c.v. or i.t.) by SR (i.c.v. or i.p.) differed significantly for only two combinations [Delta8-THC/SR, both i.c.v. and CP55 (i.t.)/SR (i.p.)]. Conversely, SR (i.t.) produced an incomplete block of the antinociceptive effects of i.t. Delta9-THC, Delta8-THC and CP55 (AD50 = 28.6, 50.2 and 20.9 microgram/mouse, respectively). Blockade of the deoxy-HU210 (i.c.v.) by SR (either i.c.v. or i.p.) was incomplete and AD50 values could not be calculated. Although the maximal blockade of deoxy-HU210 (i.t.) by SR (i.t.) was only 50%, SR administered i.p. before deoxy-HU210 (i.t.) produced a potent and complete blockade (AD50 = 0.4 mg/kg). The effects of SR on ANA-induced antinociception were mixed. The maximal attenuation of the ANA (i.t.) by SR (i.t.) was 38%. SR (i.p.) blockade of ANA was complete, but the AD50 was 15.4 mg/kg, greater than 15-fold higher than that required to block Delta9-THC, Delta8-THC, CP55 or deoxy-HU210. In addition, SR (i.p. or i.t.) failed to block the hypothermic effects of ANA (i.t.), while completely reversing the hypothermic effects of Delta9-THC (i.t.). These data indicate that SR has a much greater efficacy at supraspinal than at spinal sites. Alternatively, such data suggest either a differential interaction of the cannabinoids at the CB1 receptor or the existence of subtypes of the CB1 receptor.

• Publication year

  1998

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  1998-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0022-3565(24)37725-0PMID 9732392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.

  1997influential reference
• Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.

  1997cited by this paper
• Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestine

  1996cited by this paper
• Characterization of two cloned human CB1 cannabinoid receptor isoforms.

  1996cited by this paper
• Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.

  1996cited by this paper
• Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.

  1996cited by this paper
• Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.

  1996cited by this paper
• Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.

  1996influential reference
• In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

  1996influential reference
• The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.

  1996influential reference
• Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.

  1996cited by this paper
• Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats

  1995cited by this paper
• Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.

  1995cited by this paper
• Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.

  1995influential reference
• Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol.

  1995cited by this paper
• Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.

  1995cited by this paper
• Anandamides: tolerance and cross-tolerance toΔ9-tetrahydrocannabinol

  1995cited by this paper
• Discriminative stimulus effects of anandamide in rats.

  1995cited by this paper
• An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*)

  1995cited by this paper
• Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord.

  1995cited by this paper
• Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.

  1995influential reference
• Antisense oligodeoxynucleotides to the κ-1 receptor block the antinociceptive effects of Δ9-THC in the spinal cord

  1995cited by this paper
• Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

  1995cited by this paper
• Search for endogenous ligands of the cannabinoid receptor.

  1994cited by this paper
• Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.

  1994cited by this paper
• Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia.

  1994cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.

  1994cited by this paper
• Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

  1994cited by this paper
• Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.

  1993cited by this paper
• Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.

  1993cited by this paper
• Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.

  1993cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Cannabinoids modulate potassium current in cultured hippocampal neurons.

  1993cited by this paper
• Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.

  1992cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992influential reference
• Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia.

  1992cited by this paper
• Spinal mechanisms ofΔ9-tetrahydrocannabinol-induced analgesia

  1992cited by this paper
• Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism.

  1991cited by this paper
• Spinal and supraspinal components of cannabinoid-induced antinociception.

  1991cited by this paper
• Cannabinoid receptor localization in brain.

  1990cited by this paper
• Nucleotide sequence of a human cannabinoid receptor cDNA.

  1990cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Manual of Pharmacologic Calculations: With Computer Programs

  1984influential reference
• A Comparison of THC, Nantradol, Nabilone, and Morphine in the Chronic Spinal Dog

  1981cited by this paper
• The Antinociceptive Effects of Intrathecally Administered Levonantradol and Desacetyllevonantradol in the Rat

  1981cited by this paper
• Intrathecal morphine in mice: a new technique.

  1980cited by this paper
• Morphine‐like ligand for opiate receptors in human CSF

  1975cited by this paper
• Narcotic antagonists in the benzomorphan series

  1964cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955cited by this paper
• A simplified method of evaluating dose-effect experiments.

  1948cited by this paper
• A METHOD FOR DETERMINING LOSS OF PAIN SENSATION

  1941cited by this paper

• Cannabinoid Regulation of Murine Vaginal Secretion

  2025cites this paper
• Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.

  2025cites this paper
• CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity

  2024cites this paper
• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

  2024cites this paper
• Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol

  2024cites this paper
• Structural Basis for Molecular Recognition of Cannabinoids by Inhibitory Cys-Loop Channels.

  2024cites this paper
• Propylene glycol and Kolliphor as solvents for systemic delivery of cannabinoids via intraperitoneal and subcutaneous routes in preclinical studies: a comparative technical note

  2023cites this paper
• Structural basis for cannabinoid-induced potentiation of alpha1-glycine receptors in lipid nanodiscs

  2022cites this paper
• Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies.

  2021cites this paper
• Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.

  2018cites this paper
• The role of the endocannabinoid system in the emotional modulation of pain

  2018cites this paper
• Cannabinoids and Pain: Sites and Mechanisms of Action.

  2017cites this paper
• Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.

  2017cites this paper
• Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling

  2016cites this paper
• Central Analgesic Activity

  2016cites this paper
• The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress.

  2015cites this paper
• Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists

  2015cites this paper
• Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors.

  2014cites this paper
• Conference on ‘ PUFA mediators: implications for human health ’ Symposium 3: Cannabinoids in human health Endocannabinoid system and pain: an introduction

  2014cites this paper
• The Endocannabinoid Anandamide Inhibits Voltage-Gated Sodium Channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus Oocytes

  2014cites this paper
• Stereodivergent total synthesis of Δ9-tetrahydrocannabinols.

  2014cites this paper
• Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-Terminally Extended Hemopressin Peptide

  2014cites this paper
• Rôle et implication du système cannabinoïde dans la modulation périphérique de la douleur inflammatoire et neuropathique

  2014cites this paper
• The Endocannabinoid Anandamide Inhibits Voltage-Gated Sodium Channels Na v 1.2, Na v 1.6, Na v 1.7, and Na v 1.8 in Xenopus Oocytes

  2014cites this paper
• Endocannabinoid system and pain: an introduction

  2013cites this paper
• Cannabinoids Facilitate the Swallowing Reflex Elicited by the Superior Laryngeal Nerve Stimulation in Rats

  2012cites this paper
• Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms.

  2012cites this paper
• Cannabinoid mediated diuresis in mice

  2011influential citation
• Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.

  2011cites this paper
• CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action

  2011cites this paper
• Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

  2011influential citation
• Neurochemistry of Endogenous Antinociception

  2011cites this paper
• The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.

  2011cites this paper
• Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.

  2011cites this paper
• Dissimilar cannabinoid substitution patterns in mice trained to discriminate &Dgr;9-tetrahydrocannabinol or methanandamide from vehicle

  2011cites this paper
• Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

  2011cites this paper
• Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.

  2011influential citation
• Effects of opioids, cannabinoids, and vanilloids on body temperature.

  2011cites this paper
• Cannabinoid rescue of striatal progenitor cells in chronic Borna Disease viral encephalitis in rats

  2011cites this paper
• Cannabinoid receptor CB1-immunoreactive nerve fibres in painful and non-painful human tooth pulp.

  2010cites this paper
• In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.

  2010cites this paper
• Cannabinoid Modulation of the Behavioral Effects of Morphine

  2010influential citation
• Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain.

  2010cites this paper
• Modulation of pain sensitivity by endogenous and exogenous ligands and by social isolation

  2010cites this paper
• Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice.

  2010cites this paper
• Dynamic regulation of the endocannabinoid system: implications for analgesia

  2009cites this paper
• The endocannabinoid system and pain.

  2009cites this paper
• Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist.

  2009cites this paper
• Targeting the cannabinoid system to produce analgesia.

  2009cites this paper
• ANTINOCICEPTIVE INTERACTIONS BETWEEN ANANDAMIDE AND ENDOMORPHIN‐1 AT THE SPINAL LEVEL

  2009cites this paper
• Cannabinoid Receptor Mediated Analgesia: Novel Targets for Chronic Pain States

  2009cites this paper
• Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.

  2008cites this paper
• The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level

  2008influential citation
• Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

  2008cites this paper
• First in Vivo Evidence for a Functional Interaction between Chemokine and Cannabinoid Systems in the Brain

  2008cites this paper
• The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.

  2007cites this paper
• Composante centrale de l’effet analgésique des AINS

  2007cites this paper
• On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).

  2007cites this paper
• Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.

  2007cites this paper
• On the Pharmacological Properties of Δ9‐Tetrahydrocannabinol (THC)

  2007cites this paper
• Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant‐induced arthritis in obese and lean rats

  2007cites this paper
• Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate

  2007cites this paper
• Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.

  2006cites this paper
• Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions

  2006cites this paper
• Neurons in a Rodent Model of Neuropathic Pain Effects of a Cannabinoid Agonist on Spinal Nociceptive

  2006cites this paper
• Effect of the tyramine fragment of opioid receptor ligands on their agonist and antagonist properties

  2006cites this paper
• Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells

  2006influential citation
• Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.

  2006cites this paper
• The Pharmacology of SR 141716A: A Review

  2006cites this paper
• Cannabinoid receptors and endocannabinoids: Evidence for new players

  2006cites this paper
• Cannabinoids suppress dendritic cell-induced T helper cell polarization

  2006cites this paper
• Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.

  2005cites this paper
• Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve

  2005cites this paper
• A cannabinoid agonist, WIN 55,212‐2, reduces neuropathic nociception induced by paclitaxel in rats

  2005cites this paper
• Therapeutic potential of cannabinoid receptor agonists as analgesic agents

  2005cites this paper
• The THC‐induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2

  2004cites this paper
• Le système endocannabinoïde central

  2004cites this paper
• CB1 receptor mediation of cannabinoid behavioral effects in male and female rats

  2004influential citation
• Evidence that CB‐1 and CB‐2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat

  2004cites this paper
• Local application of the cannabinoid receptor agonist, WIN 55,212–2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non‐nociceptive neurons

  2004influential citation
• CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats.

  2004cites this paper
• A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

  2004cites this paper
• Cannabinoids modulate ultrasound-induced aversive responses in rats

  2004cites this paper
• Characterization of Cannabinoid Modulation of Sensory Neurotransmission in the Rat Isolated Mesenteric Arterial Bed

  2004cites this paper
• The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801.

  2003cites this paper
• Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats.

  2003cites this paper
• Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats

  2003cites this paper
• Molecular Biology Of Drug Addiction

  2003cites this paper
• A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain

  2003cites this paper
• New Advances in the Identification and Physiological Roles of the Components of the Endogenous Cannabinoid System

  2003cites this paper
• The cannabinoid system: a role in both the homeostatic and hedonic control of eating?

  2003cites this paper
• Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.

  2002cites this paper
• Cannabinoids: a real prospect for pain relief?

  2002cites this paper
• [The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?].

  2002cites this paper
• CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.

  2002cites this paper
• Pharmacological plasticity associated with neuropathic pain states

  2002cites this paper
• Pharmacologie des dérivés cannabinoïdes : applications au traitement de la douleur ?

  2002cites this paper
• Inhibition of Improgan Antinociception by the Cannabinoid (CB)1 AntagonistN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of Obligatory Role for Endocannabinoids Acting at CB1 Receptors

  2002cites this paper
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cites this paper
• Analgesic, anti-inflammatory, and anti-pyretic activity1

  2002cites this paper